Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.90
Bid: 2.80
Ask: 3.00
Change: 0.05 (1.75%)
Spread: 0.20 (7.143%)
Open: 2.80
High: 2.90
Low: 2.74
Prev. Close: 2.85
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

Wed, 27th Mar 2024 11:02

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Norman Broadbent PLC, up 13% at 8.75 pence, 12-month range 4.50p-9.32p. The London-based recruitment firm swings to a pretax profit in 2023 of GBP309,000 from a loss of GBP338,000 in 2022. This tracks revenue rising 41% to GBP12.3 million from GBP8.7 million, partially offset by operating expenses rising 34%to GBP10.2 million from GBP7.6 million and cost of sales rising 21% to GBP1.7 million from GBP1.4 million. Chief Executive Officer Kevin Davidson comments: "We have taken the opportunity to invest further in the Company, hiring exceptional people and building our platform to take advantage of the market rebound when it comes. Our ambition remains steadfast and we will continue to pursue our aggressive growth strategy, whilst remaining profitable and cash positive, both organically and potentially through synergistic M&A opportunities...Supported by our considerable brand strength and market leading processes and technologies, we are well-positioned for continued success."

----------

Allergy Therapeutics PLC, up 11% at 3p, 12-month range 0.37p-3.20p. In the six months that ended December 31, the Sussex, England-based biotechnology company reports pretax loss widening to GBP14.9 million from GBP8.2 million a year earlier. Revenue falls 16% to GBP33.6 million from GBP39.9 million, while financial expenses soar to GBP3.2 million from GBP398,000. Chief Executive Officer Manuel Llobet comments: "2023 has been an important year, marked by a highly focused approach to our business priorities, and a steadfast commitment to our Grass and Peanut allergy research & development programmes. We have navigated the challenges of last year, resulting in more streamlined operations and improved cost-effectiveness. This progress starts to pave the way towards a return to growth." Allergy Therapeutics also notes that its lenders have agreed that a further GBP15 million may be drawn from the existing GBP40 million amended loan facility from the second quarter of calendar 2024, with the first GBP7.5 million having already been drawn down. It says this extends its cash runway into the first quarter of its financial 2025. The lenders are major shareholders SkyGem Acquisition, which is an affiliate ZQ Capital Management, alongside Southern Fox Investments.

----------

AIM - LOSERS

----------

Infrastructure India PLC, down 80% at 0.10p, 12-month range 0.10p-1.27p. In the six months that ended September 30, the infrastructure fund investing directly into assets in India reports pretax loss narrowing to GBP31.5 million from GBP62.2 million a year earlier, largely driven by foreign exchange loss narrowing to GBP3.7 million from GBP40.8 million. Shares restarted trading on Wednesday after publishing its annual results for the financial year ended March 31 on Tuesday. During this period, pretax loss widened to GBP59.2 million from GBP48.4 million a year earlier. The company says: "The group has prepared the interim results on a basis other than going concern due to the uncertainty in relation to the timing of potential transactions, ultimate receipt of sale proceeds and the specifics of any deferred consideration. This basis was considered the most appropriate method for the reporting period."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
27 Mar 2024 16:13

EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
12 Mar 2024 14:06

Allergy Therapeutics starts dosing patients in peanut allergy trial

(Alliance News) - Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect trial.

Read more
1 Mar 2024 15:49

UK shareholder meetings calendar - next 7 days

Monday 4 March 
Ascent Resources PLCGM re bonus issue of preference shares
JPMorgan Emerging Europe, Middle East & Africa Securities PLCAGM
Lexington Gold LtdAGM
Tuesday 5 March 
Ajax Resources PLCGM re extension of investment mandate
Beowulf Mining PLCGM re capital raise
CC Japan Income & Growth Trust PLCAGM
Driver Group PLCAGM
Edinburgh Worldwide Investment Trust PLCAGM
Jersey Electricity PLCAGM
Wednesday 6 March 
Ecofin Global Utilities & Infrastructure Trust PLCAGM
Mila Resources PLCAGM
Paragon Banking Group PLCAGM
Thursday 7 March 
Asia Strategic Holdings LtdAGM
CT UK Capital & Income Investment Trust PLCAGM
Henderson Opportunities Trust PLCAGM
XPS Pensions Group PLCGM re directors' remuneration policy 2024
Friday 8 March 
Allergy Therapeutics PLCAGM
All Things Considered Group PLCAGM
Chenavari Toro Income Fund LtdAGM
Neo Energy Metals PLCAGM
Schroder UK Mid Cap Fund PLCAGM
Silverwood Brands PLCGM re proposed share capital reduction
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
14 Feb 2024 10:22

Allergy Therapeutics forecasts revenue drop but trials going well

(Alliance News) - Allergy Therapeutics PLC on Wednesday said revenue decreased in its latest half year, and expects to require further funding soon.

Read more
5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
30 Jan 2024 10:38

Allergy Therapeutics resumes trading on AIM; annual revenue plunges

(Alliance News) - Allergy Therapeutics PLC on Tuesday resumed trading on AIM after the release of its annual results.

Read more
27 Dec 2023 14:17

IN BRIEF: Allergy Therapeutics amends facility, plans warrant issue

Allergy Therapeutics PLC - Sussex-based biotechnology company specialising in allergy vaccines - Shares rise as firm enters amendment to the facility agreement it reached in early April with SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Deal provides Allergy Therapeutics with a GBP40 million secured loan facility of which GBP32.5 million is uncommitted. Facility is available to drawdown between January 15 and the same day in 2026, with interest payable semi-annually at 12% per year and a January 15, 2027 repayment date.

Read more
15 Dec 2023 21:09

EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
13 Dec 2023 10:11

Allergy Therapeutics shares jump as hails grass allergy jab data

(Alliance News) - Allergy Therapeutics PLC on Wednesday said that phase-3 trials of its grass allergy injection yielded positive results, moving the product closer to market entry.

Read more
13 Dec 2023 09:55

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
14 Nov 2023 11:56

Allergy Therapeutics says allergy therapy trial meets primary endpoint

(Alliance News) - Allergy Therapeutics PLC on Tuesday said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary endpoint.

Read more
14 Nov 2023 10:59

AIM WINNERS & LOSERS: Renalytix revenue halves; DP Poland trades well

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
6 Nov 2023 12:33

IN BRIEF: Allergy Therapeutics extends cash runway until end of 2023

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.